# STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia

> **NCT00006052** · PHASE2 · COMPLETED · sponsor: **Novartis**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00006052
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-06
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2014-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006052, "STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous Leukemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00006052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*